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Abstract There has been an increase of anti-ulcer drug
consumption in Spain. A high proportion of this con-
sumption may be due to the use of those drugs as
gastroprotective agents when co-prescribed with non-
steroidal anti-inﬂammatory drugs (NSAIDs). The aim
of this study was to learn how these treatments are
being used: the prevalence of use, the type of drug and
the main features of patients. A sample of patients
going to pharmacies with a NSAID prescription, with
or without a gastroprotective agent, was obtained. A
survey questionnaire was distributed to learn clinical
and demographic data of the patients. Of the 942
patients interviewed, 41.6% were co-treated with a
gastroprotective agent in addition to the NSAID. Most
of these patients received proton-pump inhibitors and,
to a lesser extent, histamine-2-receptor antagonists,
antacids and prostaglandin analogues. The use of gas-
troprotective agents increased with age, treatment
duration and illness chronicity; specialists prescribed a
higher proportion of those co-treatments than did
general practitioners. There was a high prescription
rate of gastroprotective agents; in general, these were
used according to recommendations. However, the type
of gastroprotective agents being used does not seem to
be justiﬁed by the current guidelines: histamine-2-
receptor antagonists and antacid drugs have not proved
their eﬃcacy in this indication. The fact that one in
four treatments with gastroprotective drugs was issued
to patients without associated risk factors identiﬁes a
possible problem where an intervention could be
appropriate.
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Introduction
The so-called gastroprotection that accompanies non-
steroidal anti-inﬂammatory drug (NSAID) prescription
is usually performed with anti-ulcer or antacid drugs.
Thus, gastrointestinal damage caused by anti-inﬂam-
matory drugs is intended to be prevented. Various
studies agree that NSAID utilization in Spain and other
countries has markedly increased during the last decade
[1, 2, 3, 4, 5, 6, 7]. It is estimated that in Spain
approximately 4 million persons take NSAIDs more or
less regularly to treat mild or moderate pain and
inﬂammation [8, 9]. However, their use is occasionally
limited by the frequency and severity of their adverse
eﬀects, which can aﬀect up to 25% of treated patients
[10]. Among these eﬀects, gastrointestinal ones should
be highlighted, ranging from mild digestive discomfort
or dyspepsia to bleeding ulcers and perforations.
In the hospital setting, the usual practice is to
administer anti-ulcer drugs to prevent the gastric impact
of certain aggressive factors, such as stress caused by the
hospital stay or the administration of some drugs. It has
been estimated that 46% of inpatients from various
Spanish hospitals received anti-ulcer or antacid drugs
[11]. In the last years, this practice is being extended to
the primary care setting, although there are no clearly
established criteria on treatment regimens or the type of
patient to be protected [1, 12]. In addition, several
studies have been published that show that anti-ulcer
drug use does not seem to suit to current scientiﬁc
knowledge. Burrull et al. [1] in 1995 reviewed a total of
205 clinical charts from an urban basic health area of
Barcelona. According to previously ﬁxed criteria, only
7.4% of NSAID-treated patients were candidates to
receive concomitant therapy for gastrointestinal pro-
tection; however, of those patients, only 40% did receive
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it. Jime´nez Plata et al. [13] analyzed 713 prescriptions of
anti-ulcer drugs from 195 primary care physicians in
Andalusia, considering their suitability to a therapeutic
protocol. They found that about half of the prescrip-
tions of anti-ulcer drugs were unjustiﬁed, the most
common reason of the excessive prescription rate of
anti-ulcer drugs being non-investigated dyspepsia and
prophylaxis of gastrointestinal lesions induced by
NSAIDs.
Interestingly, both in primary care and hospital set-
tings, an increase in the prescription rate of anti-ulcer
drugs has been detected, particularly proton-pump
inhibitors and histamine-2 (H2)-receptor antagonists.
Also, it has been reported that the consumption of anti-
ulcer drugs in Spain had increased from 5 deﬁned daily
doses per 1000 inhabitants per day in 1988 to 19 in 1997
[14]. Some of these studies reported that one of the
causes of this increase was their use in the prophylaxis of
NSAID-induced gastrointestinal lesions [8, 15].
In summary, various problems related to the utiliza-
tion of gastroprotective medication, including doubts
about its eﬀectiveness, use suitability, safety or high cost,
can result in an inadequate consumption of this
medication. We think that their study can contribute to
a better use of these drugs and, consequently, a greater
beneﬁt to patients. Therefore, we intended to learn the
utilization proﬁle of the so-called gastroprotective
drugs (antacids, H2-receptor antagonists, proton-pump
inhibitors and misoprostol) associated with the treat-
ment with NSAIDs in outpatients. Other objectives were
to learn the therapeutic groups and active ingredients
used as gastroprotective, describe clinical and demo-
graphic characteristics of the population to which these
drugs are prescribed and estimate the incidence of the
association of gastroprotective drugs with NSAIDs.
Materials and methods
This was a drug-utilization study (prospective, cross-
sectional) carried out by means of a structured survey
administered in a group of pharmacies to the patient to
whom the medication had been prescribed or to a rela-
tive who had gone to get the drug and knew the patient’s
clinical condition. When considered necessary, the
questionnaire was complemented by a telephone inter-
view. Several pharmacies of Valladolid and Leo´n prov-
inces, through their license holders, agreed to participate
in the study. The subjects included were patients of
either sex, older than 14 years, who were prescribed a
NSAID treatment. Through the survey, information on
history of gastrointestinal disorders, as well as the
patient’s medication, was obtained, including prescrip-
tion of NSAIDs, gastroprotective drugs and other
associated medication (corticosteroids, anticoagulants
and antiplatelets) as well as indication, dose and dura-
tion of treatment. Socio-demographic and other clinical
characteristics of patients prescribed a NSAID with or
without a gastroprotective agent were also collected.
Likewise, information on personal characteristics such
as sex, age, education level, cigarette smoking and social
security status was collected.
To avoid selection bias (administering questionnaires
preferably to those patients having no co-prescription),
clear and repeated explanations were given to pharma-
cists on the main objective of the study. In addition, they
were asked to administer the questionnaires to previ-
ously deﬁned patients, e.g., the ﬁrst three to arrive, those
who came during the last hour of the business day and
so on.
The estimated sample size was 598 subjects; for the
estimate we assumed an a-error of 0.05, a precision of
4% and for the worst situation concerning use preva-
lence of a gastroprotective agent, 50%. The patient
recruitment took place between September 2001 and
July 2002.
A descriptive data analysis was carried out: use
prevalence of gastroprotective agents, type of agents and
a patient proﬁle. Also, chi-square tests and means
(Student’s t-test) were performed. A univariant analysis
of factors associated with the prescription of gastro-
protective agents was also done: estimation of the odds
ratio (OR), conﬁdence interval (CI) and a multivariate
analysis to learn the weight of potential determinants of
gastroprotective agent prescription depending on the
physician, health care setting and patient characteristics.
Results
During the period November 2001–July 2002, 942
questionnaires from 33 diﬀerent pharmacies participat-
ing in the drug-utilization study were collected, of which
920 were valid; the mean number of questionnaires per
pharmacy was 27.9 (SD, 19.4).
Gastroprotective medication, in addition to NSAIDs,
was received by 41.6% of patients (n=383); the esti-
mation for the reference population ranged between
39.4% and 43.8%. Most of the patients received proton-
pump inhibitors and, to a lesser degree, H2-receptor
antagonists, antacids and prostaglandin analogues
(Table 1). The mean age of the patients to whom
gastroprotective agents were prescribed was 61.7 years;
the patients who did not receive this co-medication were
4.7 years younger (Table 2). The use of gastroprotection
increased with age, treatment duration and the chronic
nature of the disease. Also, in the specialized care
setting, these gastroprotective drugs were prescribed in a
higher proportion. A history of gastrointestinal disor-
ders and the concomitant use of antiplatelets were also
associated with more prescriptions of gastroprotective
agents.
The adjusted weight of various factors in relation to
gastroprotection is shown in Table 3: the history of
gastrointestinal disorders was associated with a high
probability of being prescribed a gastroprotective drug
(OR=9.0; 95% CI, 6.0–13.5). However, an acute
condition such as transient headache was associated
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with a high probability of not being prescribed a gas-
troprotective drug (OR=0.4; 95% CI, 0.1–1.0). After
adjustment for various confusion factors, diclofenac,
aceclofenac, naproxen and ibuprofen, in this order, were
associated with a higher probability of being prescribed
a gastroprotective agent, although signiﬁcant diﬀerences
were not detected (Table 4).
With the data collected, a predictive model of
logistic regression has been built, with which we can
estimate probabilities as a function of the various
patient characteristics or the health care setting where
the prescription was done (logit=1.901+0.015·age–
0.974·headache+0.725·specialist+1.133 · corticoster-
oids+2.205·history); thus, a patient younger than
25 years, who goes to a primary care physician due to
a headache, has no history of gastrointestinal disor-
ders and is not being treated with corticosteroids has a
7.6% probability to be prescribed, in addition to the
NSAID, a gastroprotective agent (Table 5). Gastro-
protection use percentage according to the number
and type of risk factors considered is shown in Fig. 1.
Discussion
The main ﬁnding of this study is the high percentage of
prescription rate of gastroprotective drugs together with
NSAIDs. A gastroprotective agent in combination with
a NSAID was prescribed to 41.6% of the analyzed
sample. The sample seems to be representative of the
population having a NSAID, since it is quite large
(n=920)—more than that estimated for a use prevalence
lower than the one we found—and because it includes a
very varied geographical spectrum, including urban and
rural areas. Although the Castilla y Leo´n population is
slightly older than those of other Spanish regions, we do
not think that this diﬀerence would signiﬁcantly change
the results if the estimation were done in other regions.
Table 2 Use of gastroprotective agents associated with
non-steroidal anti-inﬂammatory drugs according to various socio-
demographic and clinical factors
Gastroprotection P value
Frequency (%)a
n=383 (41.6)
Age (mean; SD) 61.7 years;
15.8 yearsb
<0.001
Age groups
<40 years 38 (25.7) <0.001
41–65 years 160 (43.1)
>65 years 185 (46.1)
Gender 0.470
Male 232 (40.8)
Female 151 (43.3)
Education level 0.013
Nonec 56 (41.2)
Primary 243 (45.1)
Secondary 52 (30.2)
University 30 (42.9)
Non-speciﬁed 2 (66.6)
Smoking habit 70 (39.3) 0.487
Cause of prescriptiond
Rheumatic condition 167 (48.5) 0.001
Headache 6 (20.0) 0.015
Trauma 33 (44.0) 0.476
Muscular pain 74 (37.0) 0.382
Other 151 (38.0) –
Duration 0.001
<15 days 79 (31.6)
15–30 days 85 (43.4)
>30 days 219 (46.3)
Concomitant medication
Corticosteroids 25 (75.8) <0.001
Anticoagulants 5 (35.7) 0.651
Antiplatelets 9 (81.8) 0.007
Health care setting
Specialized 159 (55.4) <0.001
General 224 (35.4)
History of gastrointestinal disorders 151 (80.3) <0.001
aPercentages refer to all individuals in the corresponding category,
those who received gastroprotective medication plus those who did
not
bFor patients without a gastroprotective agent, 57.1 years (SD,
18.7 years)
c‘‘None’’ is the category for those who did not ﬁnish primary
education
dMore than one cause of prescription was possible
Table 1 Utilization pattern of gastroprotective drugs associated
with non-steroidal anti-inﬂammatory drug treatment (n=383)
Gastroprotective agent Frequency (%)
Proton-pump inhibitors 221 (57.7)
Lansoprazole 56 (14.6)
Omeprazole 146 (38.1)
Pantoprazole 15(3.9)
Rabeprazole 4 (1.0)
H2-receptor antagonists 107 (27.9)
Ranitidine 75 (19.6)
Famotidine 32(8.4)
Antacid drugs 40 (10.4)
Zinc acexamate 2 (0.5)
Algeldrate 1 (0.3)
Almagate 34 (8.9)
Dihydroxyaluminium aminoacetate 1 (0.3)
Magaldrate 2 (0.5)
Prostaglandin analogues 10(2.6)
Misoprostol 10(2,6)
Non-speciﬁed/other 5(1.3)
Table 3 Determinant factors in the utilization of gastroprotective
drugs associated with non-steroidal anti-inﬂammatory drug treat-
ment
Factor Adjusted odds ratio
(95% conﬁdence interval)a
Cause of prescription:
headache
0.4 (0.1–0.99)
Specialized care 2.1 (1.5–2.9)
Age >65 years 2.4 (1.5–3.8)
Associated corticosteroids 3.0 (1.2–7.2)
Associated antiplatelets 4.5 (0.9–23.0)
History of gastrointestinal
disorders
9.0 (6.0–13.5)
aAge-adjusted odds ratio, categorized into three categories: type of
medical care, headache as a cause of non-steroidal anti-inﬂamma-
tory drug prescription, history of gastrointestinal disorders, asso-
ciated corticosteroids and associated antiplatelets
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In a study carried out in a basic health area of
Hospitalet de Llobregat, Barcelona (Spain), in 1994, a
clinical chart review found that 16.6% of patients who
were prescribed a NSAID received also a gastropro-
tective agent [1]; in this case, the H2-receptor antago-
nists were the most used (41.1%) and, to a lesser
degree, misoprostol and omeprazole (6% each). Obvi-
ously, both the use percentage of gastroprotection and
the pattern of drugs used have changed markedly.
According to the use pattern observed in the present
study, proton-pump inhibitors would be currently the
gastroprotective agents used more often—nearly 60%
of all cases. It is worthwhile to emphasize, however,
that H2-receptor antagonists and antacids, which have
not proved their eﬃcacy in clinical trials nor in
observational studies [16], are used in quite high per-
centages. In our study, they represented nearly 40% of
the total; in addition, their safety should be considered
[17, 18, 19].
Similarly, other studies carried out in diﬀerent
countries have addressed the use of gastroprotective
medication. The percentage of people aged 65 years and
higher who received a gastroprotective agent diﬀerent
from misoprostol was 22.9 in 1992 in Quebec (Canada)
[3] and 17.1 in Nova Scotia (Canada) during 1993 and
1994 [4]. This ﬁgure was 21.7% in patients admitted to
medical wards through an emergency department in
Ireland in 1996 (median age, 70.5 years) [5]. In France,
with a sample of 791 prescriptions from general practi-
tioners from the Coˆte d’Or, co-prescription was found in
29.5% in 1999 [6]. More recently, in the USA, in a co-
hort of patients with arthritis treated with NSAIDs,
42% had a co-prescription [7].
The use of gastroprotective medication increased
with risk factors known to cause gastrointestinal lesions:
age, history of gastrointestinal disorders, use of corti-
costeroids or concomitant use of antiplatelets (Fig. 1).
Antiplatelet use was associated with more prescriptions
of gastroprotective agents, although this was not so with
anticoagulants. Also, the setting in which medical care
took place inﬂuenced markedly on prescriptions: after
adjusting for all possible confusion factors, the proba-
bility of being prescribed a gastroprotective agent in T
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Table 4 Use of gastroprotection by non-steroidal anti-inﬂamma-
tory drug (NSAID) type
NSAID Adjusted odds ratio
(95% conﬁdence interval)a
Rofecoxib 1
Aspirinb 1.2 (0.5–2.6)
Piroxicam 2.1 (0.8–5.1)
Celecoxib 2.1 (0.9–4.8)
Ibuprofen 2.9 (1.3–6.6)
Naproxen 3.4 (1.5–7.7)
Aceclofenac 3.5 (1.5–7.8)
Diclofenac 3.9 (1.8–8.3)
aAge-adjusted odds ratio, type of medical care, headache as a cause
of prescription and history of gastrointestinal disorders
bDose ‡300 mg/day
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combination with a NSAID in the specialized care set-
ting was double that observed in primary care. This can
be due to a greater restraint of primary care physicians,
who are perhaps more sensitive to warnings on problems
arisen by excessive pharmaceutical spending, to the
practice of a more defensive medicine by specialists or
perhaps to a spurious mechanism due to an insuﬃcient
adjustment. It could be possible that the most severe
patients, as should be expected, are visited by the spe-
cialist and the adjustment performed is unable to neu-
tralize that severity factor.
It is diﬃcult to select clear criteria to assess pre-
scription appropriateness. This diﬃculty lies in the
complexity and diversity of clinical conditions not prone
to be classiﬁed with necessarily rigid criteria. At any
rate, it is easier to estimate what proportion of the pa-
tients that show no risk factors have been treated with
gastroprotective medication. In our study, this propor-
tion was 25%. There exists, however, a trend to use
more gastroprotective drugs when the number of risk
factors increases in patients (Fig. 1).
When individual NSAIDs are considered, diclofenac,
aceclofenac, naproxen and ibuprofen, in this order, are
associated with a higher probability of being prescribed
a concomitant gastroprotective agent. However, CIs of
estimated risk values overlap, and there seems not to
exist signiﬁcant diﬀerences in this respect.
A surprising fact observed in this study is the pre-
scription of gastroprotective drugs combined with the
selective COX-2 inhibitors, rofecoxib and celecoxib, in
large proportions. These drugs have been marketed as
agents with a lesser risk to produce gastrointestinal le-
sions and were prescribed with a gastroprotective drug
in 33.9% and 45.9% of the occasions, respectively. It
could be thought that they are used in patients with a
higher risk, which we have been able to note in our
study, and that, consequently, they are also associated
with a gastroprotective agent in an apparently ‘‘double
protection.’’
The consumption of anti-ulcer and antacid drugs,
used for gastroprotection, has experienced a substantial
increase in the last years [14]. Gastroprotection against
the risk of gastrointestinal lesions produced by NSAIDs
represents 41.3% of the consumption of these anti-ulcer
and antacid drugs [2]; this was estimated through
information derived from clinical charts of six health
centers of Navarra in 1997.
One of the limitations of our study could be the fact
that the participating pharmacists administered the
questionnaires preferably to the patients coming with
only one prescription, since by doing so, the question-
naire would become easier to complete; this would
account for a selection bias that could be considered as
‘‘laziness bias’’ and was dealt with as stated above. The
high prevalence of gastroprotective medication use,
however, leads us to think that there has not been such a
selection bias. In addition, being a cross-sectional and
prospective study designed to ﬁnd out the prevalence
and pattern of gastroprotective drug use, its ﬁndings are
more reliable than those obtained by means of retro-
spective studies taking advantage of data that were not
collected with that purpose.
In conclusion, there seems to exist a high prescription
rate of gastroprotective agents that, in general, follow
recommended criteria. However, the type of gastropro-
tective agent used does not seem to be justiﬁed by lit-
erature data: H2-receptor antagonists and antacids have
not reliably demonstrated their eﬃcacy in this indica-
tion. The fact that one-quarter of treatments with gas-
troprotective agents are received by patients that do not
show a priori risk factors identiﬁes a potential problem
on which an intervention could be carried out to discuss
and change, if necessary, this prescription pattern.
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Fig. 1 Percentage of gastroprotection use by the number and type
of risk factors considered (none 25.8; age 35.7; corticosteroids 66.7;
previous history 78.4; corticosteroids and previous history 75; age
and corticosteroids 77.8; age and antiplatelets 80; age and previous
history 80.9; age, corticosteroids and previous history 100; age,
antiplatelets and previous history 100). For antiplatelets as a
unique risk factor, there was only one non-treated patient
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